Apexigen successfully listed on Nasdaq!
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of Nasdaq successfully and presented in stock code “APGN” this evening, August 1st, Beijing time. In July 2018, Efung Capital was one of the players of Apexigen's Series C financing.Headquartered in San Carlos, CA, Apexigen is a clinical-stage biopharmaceutical company. It focuses on inventing the new generations of antibodies that target on cancer immunotherapies. The Corporation possesses a distinctive antibody drug development platform, APXiMAB, which is currently being developed for its core product-APX005M- additional with pre-clinical programs.The development platform enables the f...
2022
-
08
-
01